ARL5A

Across TCGA pan-cancer cohorts, ARL5A RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ARL5A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ARL5A RNA is repressed in tumor relative to normal tissue. In most cancer types ARL5A is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, LIHC, and CHOL are the cancer types where ARL5A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL5A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	All	−0.693	<.001	10	view →
LIHC	All	All	+0.423	<.001	6	view →
CHOL	Male	All	+1.401	<.001	5	view →
KICH	All	All	−0.688	<.001	4	view →
BRCA	All	II,III,IV	+0.204	.005	4	view →
COAD	Male	All	+0.438	.002	3	view →
LUAD	Female	II,III,IV	−0.516	.005	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ARL5A–THCA

Open the THCA breakdown →